Top-Rated Analysts

American Airlines Remains Our Top Pick In The Sector, Says Imperial Capital

In a research report issued today, Imperial Capital analyst Bob Mcadoo maintained an Outperform rating on American Airlines (NASDAQ:AAL) with a price target …

UPDATE: Cowen Reiterates Outperform On BIND Therapeutics Following Clinical Updates

Cowen’s healthcare analyst Eric Schmidt is weighing in with some thoughts on BIND Therapeutics (NASDAQ:BIND), as the company yesterday announced an upbeat strategic overview for 2015, along with …

Biogen: Lingo ‘Success’ Is Not A Relevant Part Of The Story, Says Piper Jaffray’s Joshua Schimmer

Piper Jaffray’s healthcare analyst Joshua Schimmer weighed in today with his thoughts on Biogen Idec (NASDAQ:BIIB), following the results from a phase 2 study of …

UPDATE: Piper Jaffray Maintains Buy On GW Pharmaceuticals Following Sativex Phase III Results

In a research report published today, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on GW Pharmaceuticals (NASDAQ:GWPH) with a price target of $147, …

Needham Comments On KaloBios Following Phase 2 KB001-A Trial Results In Cystic Fibrosis

In a research report sent to investors today, Needham analyst Alan Carr reiterated a Hold rating on KaloBios Pharmaceuticals (NASDAQ:KBIO), as the company yesterday …

Needham Lifts Cempra Price Target As Solithromycin Phase 3 Trial Meets Primary Endpoint

Needham analyst Alan Carr weighed in today on shares of Cempra (NASDAQ:CEMP) maintaining a Buy rating and raising the price target to $42 (from $28), as the company announced positive …

Piper Jaffray Comments On Gilead Sciences As Express Scripts Picks AbbVie For Hepatitis C Drug

In a research report issued today, Piper Jaffray analyst Joshua Schimmer weighed in with his thoughts on Gilead Sciences (NASDAQ:GILD), following the news that Express Scripts (NASDAQ:ESRX) has …

Needham Maintains Hold On Cubist Pharmaceuticals Following Zerbaxa FDA Approval

In a research report issued today, Needham analyst Alan Carr maintained a Hold rating on Cubist Pharmaceuticals (NASDAQ:CBST), following last Friday’s news that  the …

Needham Doubles Cempra Price Target Ahead Of Solithromycin Phase 3 Results

In a research report sent to investors today, Needham analyst Alan Carr maintained a Buy rating on Cempra (NASDAQ:CEMP) and raised his price target …

Needham Raises Acadia Price Target On The Back Of Expected Milestones In 2015

In a research report published this morning, Needham analyst Alan Carr maintained a Buy rating on Acadia (NASDAQ:ACAD) and raised his price target …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts